Connexin 43-autophagy loop in the podocyte injury of diabetic nephropathy

JIALING JI1*, YAJIE ZHAO1*, CHEN NA2*, MIN YANG3, XIANYI ZHU1, HUIMIN SHI1, WEIHUA GAN1 and AIQING ZHANG1

1Department of Pediatric Nephrology, 2nd Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210003; 2Department of Pediatrics, Yanan Hospital Affiliated to Kunming Medical University, Kunming, Yunnan 650000; 3Department of Nephrology, Comprehensive Laboratory, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213000, P.R. China

Received March 16, 2019; Accepted August 23, 2019

DOI: 10.3892/ijmm.2019.4335

Correspondence to: Dr Weihua Gan or Dr Aiqing Zhang, Department of Pediatric Nephrology, 2nd Affiliated Hospital of Nanjing Medical University, 262 Zhongshanbeilu, Nanjing, Jiangsu 210003, P.R. China
E-mail: weihuagan@njmu.edu.cn
E-mail: njaiqing@njmu.edu.cn
*Contributed equally

Abstract. The reduction of podocyte injury is a key strategy in controlling proteinuria, which is the main early clinical manifestation of diabetic nephropathy (DN). Impaired autophagic flux is the primary mechanism responsible for podocyte injury in DN. The aim of the present study was to elucidate the effect of connexin 43 (Cx43) on impaired autophagic flux in podocyte injury and to explore its molecular mechanism of action in DN. Sprague-Dawley rats were administered streptozocin (STZ) to construct a DN animal model. Podocytes were incubated in media containing either buffer or high glucose (HG; 30 mM) for variable time periods. The podocytes were then examined and the mechanism of injury was investigated using an Annexin V/PI assay, immunofluorescence staining, western blotting, and RNA interference.

In vivo, STZ-induced DN rats with or without Cx43 knockdown were established to observe the role of Cx43 in autophagic flux and podocyte injury. We observed that HG induced podocyte injury, accompanied by increases in Cx43 expression and impaired autophagic flux, as evidenced by the accumulation of LC3II/LC3I and p62. Interestingly, the silencing of Cx43 expression ameliorated autophagic flux impairment and reduced podocyte injury via suppression of the mammalian target of rapamycin pathway. Furthermore, impaired autophagic flux also blocked the degradation of Cx43. In vitro studies indicated that higher numbers of Annexin V/PI-positive podocytes, impaired autophagic flux and increased Cx43 expression were observed in HG-induced podocyte injury relative to the control group. The pathogenic effect of Cx43 on impaired autophagic flux and podocyte injury was also confirmed by Cx43 knockdown. The present study provided preliminary evidence indicating that the interdependence of Cx43 and impaired autophagic flux represents a novel mechanism of podocyte injury in DN. Hence, the Cx43-autophagy loop is a potentially relevant therapeutic target for the treatment of DN.

Introduction

Diabetic nephropathy (DN) is a leading cause of chronic kidney disease (CKD) and end-stage renal failure, constituting a major health concern worldwide (1). Damage to the glomerular filtration unit is one of the most important pathological characteristics of DN. The filtration unit comprises capillary endothelial cells, the glomerular basement membrane and podocytes, which are specialized epithelial cells. Once considered to be primarily quiescent and terminally differentiated cells, podocytes have been identified as a key factor in DN (2). Podocyte injury is characterized by the pathological loss of regularity in branching and widening of the foot processes, termed ‘foot process effacement’. Severe insults lead to podocyte loss by apoptosis or detachment. Numerous studies have reported that disruption of multiple renal signaling pathways is crucial for the progression of such pathological damage (3,4). However, there are currently no effective therapeutic options for DN in the clinical setting. Indeed, the precise regulatory signaling pathways through which podocytes are injured in DN are largely unclear.

Autophagy is a major catabolic pathway through which mammalian cells degrade and recycle macromolecules and organelles. The major roles of autophagy are the removal of damaged organelles, degradation of proteins, and reconstitution of intracellular metabolism for the maintenance of intracellular homeostasis and cell health (5). Generally, autophagy is upregulated under conditions of oxidative stress and hypoxia in podocytes. Recently, convincing evidence indicates that, in the case of diabetes, autophagy plays a pivotal role in maintaining the homeostasis of lysosomes in
podocytes. The impairment of autophagy, as it is implicated in the pathogenesis of podocyte loss, may lead to massive overflow proteinuria in DN (6-8). However, the exact role of autophagy in podocytes remains elusive.

Connexins (Cx) are a multigenic family of transmembrane proteins that form gap junctions and participate in the exchange of information between cells. Connexin 43 (Cx43) is considered to be the most abundant and widely expressed gap junction protein. Extensive studies have revealed that, in addition to its role in intercellular communication, Cx43 mediates gene transcription, cytoskeleton dynamics, ATP exocytosis, vesicle release and cell stress (9). Sawai et al (10) reported the presence of Cx43 in normal podocytes in a linear pattern, and demonstrated a shift in this linear distribution in patients with DN. Our previous studies also indicated that upregulation of Cx43 is involved in podocyte injury (11), suggesting that Cx43 may be a critical regulator in podocytes under DN conditions. Furthermore, Cx43 has recently been implicated in inflammation and fibrosis. Inhibiting Cx43 may alleviate kidney damage and maintain renal function. Therefore, new therapies targeting Cx43 blockade in ideal cell populations may be a viable option for effectively inhibiting the progression of CKD (12). Interestingly, Cx43 rapidly modulates autophagy response, playing a critical role in cell apoptosis (13). However, the effect of Cx43 on the regulation of podocyte autophagy under DN conditions remains unclear.

The aim of the present study was to determine the effect of Cx43 on impaired autophagic flux, and to determine whether the regulation of Cx43 can protect podocytes under DN conditions.

Materials and methods

Antibodies and reagents. Rapamycin (RP) and chloroquine (CQ) were purchased from Sigma-Aldrich; Merck KGaA. Antibodies against LC3, mammalian target of rapamycin (mTOR) and p-mTOR were acquired from cell Signaling Technology, Inc. Anti-Cx43, anti-podocin, anti-nephrin and anti-p62 antibodies were obtained from Abcam. Anti-GAPDH was purchased from CWBio.

Animals. The study protocols were reviewed and approved by the Institutional Animal Care and Use Committee of Nanjing Medical University. A total of 24 male Sprague-Dawley rats (aged 5-6 weeks and weighing ~190 g) were housed under specific pathogen-free conditions at optimal temperature with a 12-h light/dark cycle, and were allowed free access to standard food and water. The rats were randomly divided into four groups: Group 1, PBS-infused rats (control, n=6); group 2, streptozocin (STZ; 60 mg/kg)-infused rats (n=6); group 3, STZ (60 mg/kg)-infused rats with scrambled siRNA (SCR, n=6); and group 4, STZ (60 mg/kg)-infused rats with Cx43 siRNA [oligodeoxynucleotide antisense (AS), n=6]. At the end of the 28-day infusion period, the rats were weighed and blood and urine samples were collected. The blood urea nitrogen and urine protein levels were analyzed according to the manufacturer's protocol (R&D Systems, Inc.). Tail capillary blood glucose levels were monitored with a glucometer (Accu-Chek Performa; Roche Diagnostics GmbH).

Cell culture. The immortalized mouse podocyte cell line MPC5 was kindly provided by Dr Junwei Yang (Nanjing Medical University) and the cells were cultured as previously described (14). Podocytes were differentiated without interferon-γ at 37°C for 14 days prior to the experiments. Differentiated podocytes were incubated in medium containing 0.1% fetal bovine serum for 24 h. The podocytes exposed to HG (30 mM) were then cultured for various time periods.

Transfection of small interference RNA. Podocytes were transfected with Cx43 siRNA (50 nM) (sense, 5'-AAAGUU GCUGCUAGCAUGAATT-3' and antisense, 5'-UUCAG UCCAGCAGCAACUUUTT-3') or negative control siRNA (sense, 5'-UUUCUCCGAACGUUCAGUAGU-3' and antisense, 5'-ACGUAGACGUUCGGAAGATT-3') for 24 h using Lipofectamine® 3000 (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. Thereafter, the level of targeting protein with knockdown of Cx43 was detected by western blotting.

Western blotting. The cells were harvested after treatment with the different compounds for the indicated times. Protein levels were detected by western blotting according to established protocols (15). Primary antibodies against Cx43 (1:1,000), LC3 (1:1,000), p62 (1:2,000), podocin (1:1,000), synaptopodin (1:1,000), mTOR (1:1,000), p-mTOR (1:1,000) and GAPDH (1:2,000) were used.

Immunofluorescence staining. Paraffin sections (3-µm) were prepared and incubated with primary antibodies against synaptopodin, Wilms' tumor-1 (WT-1) and p-mTOR in PBS containing 1% BSA overnight at 4°C after blocking with 5% BSA for 1 h. Subsequently, the sections were incubated with secondary antibody in PBS containing 1% BSA in the dark. After washing with PBS, cell nuclei were stained with DAPI. Immunostained samples were visualized under a fluorescence microscope (Nikon Corporation).

Immunohistochemistry. Paraffin-embedded sections were used for immunohistochemistry. Briefly, the sections were incubated with primary antibodies against Cx43 and podocin overnight at 4°C. The sections were then analyzed using a streptavidin peroxidase detection system (Maixin) according to the manufacturer's protocol. Reactions were conducted using a DAB substrate kit (Maixin) and counterstaining was performed using hematoxylin. The sections were visualized under a microscope (Nikon Corporation).

Statistical analysis. Data are presented as the mean ± the standard error of the mean. When more than two groups
were compared, one-way analysis of variance followed by Bonferroni's correction was employed to analyze the differences using SPSS 22.0 statistical software (IBM Corp.). A two-sided P-value of <0.05 was considered to indicate statistically significant differences.

Results

Cx43 silencing attenuates HG-induced podocyte injury. It was observed that podocyte injury increased significantly in the HG group, as did the expression of Cx43, suggesting that abnormal activation of Cx43 may be involved in HG-induced podocyte injury. To examine this hypothesis, Cx43 function was inhibited with Cx43 siRNA in the podocytes. siRNA-control served as a negative control. Interestingly, following transfection with Cx43 siRNA, we observed that, compared with the siRNA-control group, podocyte injury was markedly attenuated, as evidenced by the number of Annexin V/PI-positive cells (green) (Fig. 1A). In addition, increased levels of podocin and synaptopodin (surrogate markers for podocytes) were observed in podocytes transfected with Cx43 siRNA via western blot analysis (Fig. 1B). These findings indicate that the inhibition of Cx43 plays a protective role against HG-induced podocyte injury.

Cx43 negatively regulates autophagic flux by enhancing mTOR signaling in HG-induced podocytes. In addition, impaired autophagic flux was also observed in HG-induced podocytes, as demonstrated by the increased expression levels of p62 and LC3II/LC3I. Convincing evidence has demonstrated that connexins play a key role in autophagosome formation (16). To examine whether Cx43 regulates autophagic flux in HG-induced podocytes, Cx43 siRNA was also used to inhibit Cx43 expression. Of note, compared with podocytes transfected with NC-siRNA, the LC3II/LC3I ratio and the level of p62 expression were markedly decreased in Cx43 siRNA-treated podocytes, as detected by western blotting, indicating that Cx43 also plays a key role in regulating autophagic flux. Subsequently, the exact mechanism of the regulatory role of Cx43 on autophagic flux was investigated.

Figure 1. Effect of Cx43 on podocyte apoptosis. Podocytes were transfected with Cx43 siRNA (60 nM) or siRNA NC and cultured in HG conditions for 24 h. (A) Annexin V-FITC-labeled injured podocytes viewed under a fluorescence microscope. Magnification, x200. (B) Representative western blots of Cx43, podocin and synaptopodin and (C) quantification of western blotting. GAPDH levels were used as standard loading controls (mean ± standard error of the mean, n=3). *P<0.05 vs. control group; †P<0.05 vs. HG + siRNA control group (Bonferroni's correction). HG, high glucose.
Accumulating evidence has demonstrated that mTOR signaling is a pharmacological target for autophagy regulation (17). Therefore, attention was focused on mTOR signaling. The results revealed that the p-mTOR/mTOR protein ratio decreased significantly in the Cx43 siRNA group (P<0.05; Fig. 2), confirming that Cx43 inhibited autophagy by activating the mTOR signaling pathway in HG-induced podocytes. Impaired autophagic flux blocks the degradation of Cx43 in HG-induced podocytes. Accumulating evidence demonstrates that Cx43 is also regulated by autophagy under certain pathological conditions (18,19), suggesting that autophagy may regulate Cx43 expression in HG-induced podocytes. To examine this hypothesis, CQ and RP, acting as an autophagy inhibitor and an autophagy inducer, respectively (20,21), were used to regulate autophagic flux. Interestingly, compared with the HG group, the level of Cx43 increased significantly in the HG + CQ group (P<0.05; Fig. 3). By contrast, the level of Cx43 decreased significantly in the HG + RP group compared with the HG group (P<0.05; Fig. 3). These results indicated that Cx43 activation is also regulated by impaired autophagic flux in HG-induced podocytes.

**Cx43 silencing improves autophagic flux in the glomeruli of DN rats.** To determine the effect of Cx43 on autophagic flux in the glomeruli in a DN model in vivo, Cx43 siRNA or scrambled negative control siRNA was administered to the rats via the tail vein. After induction of diabetes, the DN rats and Cx43 siRNA-treated DN rats were compared in terms of body weight, blood urea nitrogen (BUN), urine protein and blood glucose levels. Of note, body weight was higher while blood glucose, urine protein and BUN levels were lower in Cx43 siRNA-treated diabetic rats compared with their control diabetic littermates (Table I). Immunohistochemical analysis revealed that Cx43 siRNA treatment significantly reduced Cx43 expression in the glomeruli (Fig. 4A). Interestingly, compared with scrambled negative control-injected mice, Cx43 siRNA administration efficiently reversed the enhanced autophagic flux, as detected by western blotting (Fig. 4B). Thus, the inhibition of Cx43 attenuated the enhanced autophagic flux in the glomeruli of rats with DN.

**Cx43 negatively regulates autophagic flux by enhancing mTOR signaling in the glomeruli of DN rats.** To examine whether mTOR signaling is involved in the regulatory effect of Cx43 on autophagic flux in vivo, mTOR levels were measured. Consistently with the results in vitro, immunofluorescence analysis revealed that the number of p-mTOR-positive cells decreased in the glomeruli of DN rats following treatment with Cx43 siRNA (Fig. 5A). Furthermore, the p-mTOR/mTOR protein ratio was markedly decreased, as confirmed by western blotting (Fig. 5B). Therefore, activation of the mTOR pathway may negatively contribute to Cx43-regulated autophagic flux.

**Cx43 silencing attenuates podocyte injury in DN rats.** To determine the role of Cx43 in podocyte injury in vivo,
immunostaining for WT-1 and synaptopodin was performed. The results revealed that the number of podocytes was significantly increased following treatment with Cx43 siRNA (P<0.05; Fig. 6A and B). Similarly, compared with the

![Figure 3. Impaired autophagic flux and Cx43 activation in HG-induced podocytes. The podocytes pretreated with CQ (10 nM) or RP (1 nM) were cultured in high glucose (HG; 30 µM) for 24 h. Representative western blots of LC3II/LC3I, p62 and Cx43 and quantification of western blotting. GAPDH levels were used as standard loading controls (mean ± standard error of the mean, n=3). #P<0.05 vs. control group; *P<0.05 vs. HG group (Bonferroni's correction). HG, high glucose; CQ, chloroquine; RP, rapamycin.]

| Groups | Body weight (g) | Blood glucose (mmol/l) | BUN (mmol/l) | Urine protein (mg/24 h) |
|--------|----------------|------------------------|--------------|------------------------|
| Control | 501.6±14.1     | 6.6±0.3                | 4.6±0.6      | 8.2±0.5                |
| DN     | 310.5±7.9      | 30.5±2.3               | 9.7±1.3      | 24.6±4.3               |
| DN + Cx43 SCR | 292.3±7.3     | 29.8±2.1      | 8.7±1.1      | 25.8±5.1               |
| DN + Cx43 AS | 433.5±8.5     | 28.7±2.3              | 5.6±0.7      | 12.8±3.1               |

*P<0.05 vs. control group; †P<0.05 vs. DN group. n=3 per group (Bonferroni's correction). BUN, blood urea nitrogen; DN, diabetic nephropathy.

![Figure 4. Effect of Cx43 silencing on podocyte autophagy. The rats were injected with STZ, followed by placement of an osmotic minipump with which to infuse Cx43 siRNA (50 µM) or NC-siRNA (50 µM) for 28 days. (A) Kidney tissue sections were subjected to histological examination via immunohistochemistry (Cx43, magnification, x400). (B and C) Western blot analysis of LC3, p62 and Cx43. The data are presented after normalization to GAPDH expression and quantified as mean ± standard error of the mean; n=3 per group; #P<0.05 vs. control group; *P<0.05 vs. DN group (Bonferroni's correction). STZ, streptozocin; DN, diabetic nephropathy.]
Figure 6. Silencing of Cx43 improved podocyte injury in DN rat model. (A and B) Representative images of WT‑1 and synaptopodin (surrogate markers for podocyte number) immunostaining in kidney sections from DN, DN + Cx43 SCR, DN + Cx43 AS and control groups (magnification, x400). (C) Kidney tissue sections were subjected to histological examination by immunohistochemistry to evaluate podocyte injury (podocin; magnification, x400). DN, diabetic nephropathy; WT‑1, Wilms' tumor‑1.

Figure 5. Cx43 negatively regulated autophagic flux by enhancing mTOR signaling in the glomeruli of a DN rat model. (A) Immunofluorescence results (magnification, x400) indicating the expression of p‑mTOR in each group. Blue, nuclear staining (DAPI); green, p‑mTOR staining. (B) Western blot analysis of p‑mTOR and mTOR. (C) Relative protein level of p‑mTOR/mTOR in the control, DN, DN + Cx43 SCR, DN + Cx43 AS groups. The data are presented as the mean ± standard error of the mean, n=3 per group; *P<0.05 vs. control group; **P<0.05 vs. DN group (Bonferroni's correction). DN, diabetic nephropathy; mTOR, mammalian target of rapamycin.
NC-siRNA-treated DN rats, podocin (a marker for podocytes) also increased after knockdown of Cx43, as assessed by immunohistochemical staining analysis (Fig. 6C). Thus, Cx43 activation appears to promote podocyte injury.

Discussion

The critical role of podocyte injury, the characteristic pathological change of DN, in the initiation and progression of DN has been recognized for several years, and impaired autophagy appears to play a key role in podocyte injury (22, 23). It was recently reported that Cx43 is involved in the autophagic process (24). However, whether Cx43 plays a critical role in podocyte autophagy in DN remains largely unknown. The present study demonstrated the involvement of increases in Cx43 expression and impaired autophagic flux in HG-induced podocyte injury. The silencing of Cx43 expression ameliorated impaired autophagic flux in the HG group, indicating that Cx43 may regulate autophagy flux by suppressing the mTOR pathway. In vitro studies indicated that the inhibition of Cx43 improved impaired autophagic flux in STZ-induced DN animal models. Furthermore, the pathogenic effect of Cx43 on podocyte injury was also confirmed. These findings may facilitate the identification of novel therapeutic targets for the treatment of podocyte injury in DN.

Autophagy (‘self-eating’) is a tightly regulated process that delivers senescent intracellular constituents to lysosomes for degradation in order to maintain intracellular homeostasis. An emerging body of research demonstrated that autophagy regulation is closely linked to human health (25, 26). Consistently with previous studies on aldosterone-induced podocyte injury (27), we herein observed that impaired autophagic flux was involved in HG-induced podocyte injury. Furthermore, increased Cx43 expression was also observed in association with this pathogenic process. However, whether Cx43 plays a critical role in impaired autophagic flux remains elusive.

Accumulating evidence has demonstrated that Cx43 may be involved in the process of podocyte injury in various kidney diseases (10,11,28). Our in vitro and in vivo data demonstrated that the expression of Cx43 was also elevated by treatment with HG, which may facilitate podocyte injury. Interestingly, after silencing Cx43 expression, HG-induced injury in cultured podocytes was partially attenuated by improving impaired autophagic flux, suggesting that Cx43 was partially involved in HG-induced podocyte injury and that the amelioration of impaired autophagic flux represents a novel mechanism mediating the effect of Cx43 on podocyte injury. However, the exact regulatory mechanisms of Cx43 on impaired autophagic flux have yet to be fully elucidated.

mTOR is a well-known master regulator of cellular metabolism, growth and proliferation in response to a wide range of triggers. The deregulation of mTOR signaling, which plays a key role in the regulation of autophagy, has been implicated in a number of human diseases, including diabetes, neurodegenerative diseases and cancer (29, 30). Interestingly, in the present study, the mTOR signaling pathway acted as a critical regulator involved in Cx43-autophagy-mediated podocyte injury in DN. It was observed that mTOR signaling was activated after stimulation with HG in vivo and in vitro, indicating that an mTOR-dependent mechanism may be involved in Cx43-mediated podocyte injury in DN, which is consistent with previous results (31, 32). Furthermore, after inhibition of Cx43 function by Cx43 siRNA, the p-mTOR/mTOR protein ratio decreased markedly, followed by a decrease in autophagic flux, indicating that Cx43 may regulate autophagy flux by negatively affecting mTOR signaling, which may be partially responsible for podocyte injury in DN.

In addition, Cx43 was found to be regulated by autophagic flux. It has been reported that the initiation of autophagy includes the formation of the phagophore, the initial sequestering compartment, which expands into an autophagosome. Completion of the autophagosome is followed by fusion with lysosomes and degradation of its contents, allowing complete flux, or flow, through the entire pathway. As RP promotes initiation of the autophagic flux, LC3I to LC3II turnover is increased in the glomeruli. Of note, LC3II is also a selective substrate of autophagy. Hence, LC3II degradation is blocked in the presence of CQ, which inhibits the acidification of organelles and, subsequently, autophagosome-lysosome fusion (33). This may explain why CQ treatment caused a greater accumulation of LC3II in the HG + CQ group when compared with the HG + RP group in the present study (even though CQ is an inhibitor of autophagy). Accordingly, compared with the HG group, the level of Cx43 increased significantly in the HG + CQ group. On the contrary, the level of Cx43 decreased significantly in the HG + RP group, indicating that a negative feedback mechanism is involved in Cx43-modulated podocyte injury to maintain the homeostasis of podocytes.

In summary, the findings of the present study uncovered a previously unknown mechanism implicated in podocyte injury under DN conditions. It was confirmed that upregulation of Cx43 expression negatively regulates autophagy by activating the mTOR signaling pathway in DN, while inhibiting Cx43 expression improved impaired autophagic flux and reduced podocyte damage. Hence, the Cx43-autophagy loop may be used as a novel therapeutic target for the development of new drugs for DN.

Acknowledgements

Not applicable.

Funding

The present study was supported by the National Natural Science Foundation of China (grant. no. 81670650); the Natural Science Foundation of Jiangsu Province Grant (grant. nos. BK20161071 and BK20161599); the Jiangsu Province Women and Children Health Key Talents (grant. nos. BK20161599); the Jiangsu Province Women and Children Health Key Talents (grant. no. FRC201737); the Nanjing Medical Science and Technique Development Foundation (grant. no. QRX17106); and the Health Commission Foundation of Jiangsu Province (grant. no. H2017002).

Availability of data and materials

The datasets analyzed during the present study are available from the corresponding author on reasonable request.
Authors' contributions
JJI, WG and AZ designed the study, performed the experiments, analyzed the results, and wrote and edited the manuscript. YZ, CN and MY performed the experiments and discussed the results. XZ and HS performed the experiments and analyzed the data. All authors read and approved the final manuscript.

Ethics approval and consent to participate
The experimental procedures in the present study were approved by Nanjing Medical University (Nanjing, China).

Patient consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References
1. Gnudi L, Coward RJ and Long DA: Diabetic nephropathy: Perspective on novel molecular mechanisms. Trends Endocrinol Metab 27: 820-830, 2016.
2. Susztak K, Raft AC, Schiffer M and Böttinger EP: Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 55: 225-233, 2006.
3. Madhusudhan T, Wang H, Dong W, Ghosh S, Bock F, Thangapandith VR, Ranjan S, Wolter J, Kohli S, Shahzad K, et al: Defective podocyte insulin signalling through p85-XBP1 promotes ATF6-dependent maladaptive ER-stress response in diabetic nephropathy. Nat Commun 6: 6496, 2015.
4. Long J, Badal SS, Ye Z, Wang Y, Ayanga BA, Galvan DL, Liu Y, Zhang J, Wang Y and Zeng X: Apelin involved in progression of diabetic nephropathy. Nat Commun 6: 6496, 2015.
5. Mizushima N and Komatsu M: Autophagy: Renovation of cells and tissues. Cell 149: 274-293, 2012.
6. Kim YC and Guan KL: mTOR: A pharmacologic target for cancer therapy: A double-edged sword of autophagy. Cancer Res 73: 651-662, 2013.
7. Wang B, Ding W, Zhang M, Li H, Guo H, Lin L, Chen J and Gu Y: Role of FOXO1 in diabetic nephropathy: A compensatory protective mechanism related to podocyte injury. Oncotarget 7: 45331-45351, 2016.
8. Haefliger JA, Demotz S, Braissant O, Suter E, Waeber B, Nicod P, Lichtenstein A, Minogue PJ, Beyer EC and Berthoud VM: Defective podocyte insulin signalling through p85-XBP1 promotes ATF6-dependent maladaptive ER-stress response in diabetic nephropathy. J Clin Invest 125: 25-32, 2015.
9. Bejarano E, Yuste A, Patel B, Stout RF Jr, Spray DC and Girão H: Role of connexin 43 in different forms of intercellular communication-gap junctions, extracellular vesicles and tunneling nanotubes. Cell Physiol Biochem 39: 217-228, 2016.
10. Bejarano E, Yuste A, Patel B, Stout RF Jr, Spray DC and Girão H: Autophagy: A pathway that contributes to connexin degradation. J Cell Sci 124: 910-920, 2011.
11. Martins-Marques T, Atanassov K, Marques C, Matai F, Perea P and Girão H: Ischaemia-induced autophagy leads to degradation of gap junction protein connexin43 in cardiomyocytes. Biochem J 467: 231-245, 2015.
12. Li C, Le L, Yang L, Yu X, He Y, Chen Z, Li L and Zhang D: Rapamycin promotes the survival and adipogenesis of ischemia-challenged adipose derived stem cells by improving autophagy. Cell Physiol Biochem 44: 1762-1774, 2017.
13. Kimura T, Takabayata Y, Takahashi A and Isaka Y: Chloroquine in cancer therapy: A double-edged sword of autophagy. Cancer Res 73: 3-7, 2013.
14. Asadulla-Mahamora M, Kume S, Tagawa A, Maegawa H and Uzu T: Emerging role of podocyte autophagy in the progression of diabetic nephropathy. Autophagy 11: 2385-2386, 2015.
15. Liu M, Liang K, Zhao J, Liu D, Wang X, Zhang W, Wei X, Zhang Y, Sun Y, Zhou Z, et al: SirT6 deficiency exacerbates podocyte injury and proteinuria through targeting Notch signaling. Nat Commun 8: 413, 2017.
16. Kim SN, Kwon HJ, Im SW, Son YH, Akindehin S, Jung YS, Lee SJ, Ryu J, Kim YJ, Seong JK, et al: Connexin 43 is required for the maintenance of mitochondrial integrity in brown adipose tissue. Sci Rep 7: 1719, 2017.
17. Kroezer G: Autophagy: A druggable process that is deregulated in aging and human disease. J Clin Invest 125: 1-4, 2015.
18. Chou AM, Ryter SW and Levine B: Autophagy in human health and disease. N Engl J Med 368: 651-662, 2013.
19. Wang B, Ding W, Zhang M, Li H, Guo H, Lin L, Chen J and Gu Y: Role of FOXO1 in diabetic nephropathy: A compensatory protective mechanism related to podocyte injury. Oncotarget 7: 45331-45351, 2016.
20. Martins-Marques T, Catarino S, Zuzarte M, Marques C, Matai F, Perea P and Girão H: Ischaemia-induced autophagy leads to degradation of gap junction protein connexin43 in cardiomyocytes. Biochem J 467: 231-245, 2015.
21. Susztak K, Raft AC, Schiffer M and Böttinger EP: Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 55: 225-233, 2006.
22. Madhusudhan T, Wang H, Dong W, Ghosh S, Bock F, Thangapandith VR, Ranjan S, Wolter J, Kohli S, Shahzad K, et al: Defective podocyte insulin signalling through p85-XBP1 promotes ATF6-dependent maladaptive ER-stress response in diabetic nephropathy. Nat Commun 6: 6496, 2015.
23. Long J, Badal SS, Ye Z, Wang Y, Ayanga BA, Galvan DL, Liu Y, Zhang J, Wang Y and Zeng X: Apelin involved in progression of diabetic nephropathy by inhibiting autophagy in podocytes. Cell Death Dis 8: e5006, 2017.
24. Kume S, Yamahara K, Yasuda M, Koyama D, Asanuma K, et al: Impaired podocyte autophagy exacerbates proteinuria in diabetic nephropathy. Diabetes 65: 755-767, 2016.
25. Liu Y, Zhang Y, Wang Y and Zeng X: Apelin involved in progression of diabetic nephropathy by inhibiting autophagy in podocytes. Cell Physiol Biochem 39: 217-228, 2016.
26. Kim SN, Kwon HJ, Im SW, Son YH, Akindehin S, Jung YS, Lee SJ, Ryu J, Kim YJ, Seong JK, et al: Connexin 43 is required for the maintenance of mitochondrial integrity in brown adipose tissue. Sci Rep 7: 7159, 2017.
27. Kroezer G: Autophagy: A druggable process that is deregulated in aging and human disease. J Clin Invest 125: 1-4, 2015.
28. Chou AM, Ryter SW and Levine B: Autophagy in human health and disease. N Engl J Med 368: 651-662, 2013.
29. Wang B, Ding W, Zhang M, Li H, Guo H, Lin L, Chen J and Gu Y: Role of FOXO1 in diabetic nephropathy: A compensatory protective mechanism related to podocyte injury. Oncotarget 7: 45331-45351, 2016.
30. Haefliger JA, Demotz S, Braissant O, Suter E, Waeber B, Nicod P and Meda P: Connexins 40 and 43 are differentially regulated within the kidneys of rats with renovascular hypertension. Kidney Int 60: 190-201, 2001.
31. Laplante M and Sabatini DM: mTOR signaling in growth control and disease. Cell 149: 274-293, 2012.
32. Shimobayashi M and Hall MN: Making new contacts: The mTOR network in metabolism and signalling crosstalk. Nat Rev Mol Cell Biol 15: 155-162, 2014.
33. Gödel M, Hartleben B, Herbach N, Liu S, Zschiedrich S, Lu S, Haefliger JA, Demotz S, Braissant O, Suter E, Waeber B, Nicod P and Meda P: Connexins 40 and 43 are differentially regulated within the kidneys of rats with renovascular hypertension. Kidney Int 60: 190-201, 2001.
34. Gödel M, Hartleben B, Herbach N, Liu S, Zschiedrich S, Lu S, Debreczeni-Mór A, Lindenmeyer MT, Rastaldi MP, Hartleben G, et al: Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J Clin Invest 121: 2197-2209, 2011.
35. Ciná dP, Onay T, Palttoo A, Li C, Maezawa Y, De Arteaga J, Jurisicova A and Quaggin SE: Inhibition of mTOR disrupts autophagic flux in podocytes. J Am Soc Nephrol 23: 412-420, 2012.
36. Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD, Adeli K, et al: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 13: 1-222, 2017.